S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?

Sigilon Therapeutics - SGTX Stock Forecast, Price & News

$0.72
-0.01 (-1.38%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.71
$0.74
50-Day Range
$0.29
$0.74
52-Week Range
$0.29
$1.90
Volume
29,503 shs
Average Volume
622,372 shs
Market Capitalization
$23.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Sigilon Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
738.8% Upside
$6.00 Price Target
Short Interest
Healthy
0.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.60) to ($1.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

127th out of 1,053 stocks

Pharmaceutical Preparations Industry

53rd out of 519 stocks


SGTX stock logo

About Sigilon Therapeutics (NASDAQ:SGTX) Stock

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive SGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGTX Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Aspect Biosystems Appoints Three New Board Members
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Yumanity cuts staff by 60%, considers a sale
Sigilon Therapeutics to lay off 40 employees
See More Headlines
Receive SGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGTX Company Calendar

Last Earnings
11/10/2022
Today
2/01/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SGTX
Fax
N/A
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+738.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-77,310,000.00
Net Margins
-444.44%
Pretax Margin
-444.43%

Debt

Sales & Book Value

Annual Sales
$9.60 million
Book Value
$2.39 per share

Miscellaneous

Free Float
31,094,000
Market Cap
$23.22 million
Optionable
Not Optionable
Beta
0.14

Key Executives

  • Dr. Rogerio Vivaldi Coelho M.B.A. (Age 59)
    M.D., MBA, Pres, CEO & Director
    Comp: $745.9k
  • Dr. Daniel G. Anderson Ph.D. (Age 53)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $46.92k
  • Mr. Philip Ashton-Rickardt Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $445.44k
  • Dr. May Orfali M.B.A. (Age 55)
    M.D., Exec. VP & Chief Medical Officer
    Comp: $536.67k
  • Dr. Robert S. Langer Jr. (Age 74)
    Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board
  • Dr. Omid Veiseh Ph.D.
    Co-Founder
  • Dr. José Oberholzer M.D.
    Co-Founder
  • Dr. Arturo Vegas Ph.D.
    Co-Founder
  • Mr. Josias Fantato De Pontes M.B.A. (Age 57)
    Acting CFO, Sr. VP, Principal Accounting Officer & Treasurer
  • Mr. Robert Windsor Jr.
    J.D., VP & Head of Investor Relations













SGTX Stock - Frequently Asked Questions

Should I buy or sell Sigilon Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SGTX shares.
View SGTX analyst ratings
or view top-rated stocks.

What is Sigilon Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price targets for Sigilon Therapeutics' stock. Their SGTX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next year. This suggests a possible upside of 727.9% from the stock's current price.
View analysts price targets for SGTX
or view top-rated stocks among Wall Street analysts.

How have SGTX shares performed in 2023?

Sigilon Therapeutics' stock was trading at $0.35 at the beginning of 2023. Since then, SGTX stock has increased by 107.1% and is now trading at $0.7247.
View the best growth stocks for 2023 here
.

When is Sigilon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our SGTX earnings forecast
.

How were Sigilon Therapeutics' earnings last quarter?

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) issued its earnings results on Thursday, November, 10th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.16. The business had revenue of $4.25 million for the quarter, compared to the consensus estimate of $2.45 million. Sigilon Therapeutics had a negative trailing twelve-month return on equity of 91.82% and a negative net margin of 444.44%.

When did Sigilon Therapeutics IPO?

(SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.

What is Sigilon Therapeutics' stock symbol?

Sigilon Therapeutics trades on the NASDAQ under the ticker symbol "SGTX."

Who are Sigilon Therapeutics' major shareholders?

Sigilon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel Griffith Anderson and Lilly & Co Eli.
View institutional ownership trends
.

How do I buy shares of Sigilon Therapeutics?

Shares of SGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sigilon Therapeutics' stock price today?

One share of SGTX stock can currently be purchased for approximately $0.72.

How much money does Sigilon Therapeutics make?

Sigilon Therapeutics (NASDAQ:SGTX) has a market capitalization of $23.52 million and generates $9.60 million in revenue each year. The company earns $-77,310,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How can I contact Sigilon Therapeutics?

The official website for the company is sigilon.com. The company can be reached via phone at 617-336-7540 or via email at robert.windsor@sigilon.com.

This page (NASDAQ:SGTX) was last updated on 2/2/2023 by MarketBeat.com Staff